| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| NGS-based RNA Sequencing Market Size 2024 |
USD 3188.5 Million |
| NGS-based RNA Sequencing Market, CAGR |
20.8% |
| NGS-based RNA Sequencing Market Size 2032 |
USD 14458.46 Million |
Market Overview:
The NGS-based RNA Sequencing market is projected to grow from USD 3188.5 million in 2024 to an estimated USD 14458.46 million by 2032, with a compound annual growth rate (CAGR) of 20.8% from 2024 to 2032.
The key drivers of the NGS-based RNA Sequencing market include the growing demand for comprehensive genomic analysis in research and clinical settings, which is propelled by the increasing prevalence of complex diseases like cancer and neurological disorders. Advances in sequencing technologies have made RNA sequencing more accessible and cost-effective, encouraging its widespread adoption. Additionally, the rising focus on personalized medicine is driving demand for RNA sequencing, as it allows for the detailed analysis of gene expression and the identification of biomarkers. The integration of RNA sequencing into drug discovery and development processes further supports market growth, as pharmaceutical companies seek more precise tools for understanding disease mechanisms and identifying therapeutic targets.
Regionally, North America holds the largest share of the NGS-based RNA Sequencing market, driven by the strong presence of major sequencing companies, significant research funding, and the early adoption of advanced genomic technologies. The United States, in particular, leads the region due to its robust healthcare infrastructure and extensive genomics research initiatives. Europe follows closely, with countries like the UK, Germany, and France contributing significantly to market growth, supported by government initiatives and growing investments in genomics research. The Asia-Pacific region is expected to witness the fastest growth during the forecast period, driven by increasing healthcare expenditures, expanding research activities, and the growing focus on precision medicine in countries like China, Japan, and India. Emerging markets in Latin America and the Middle East & Africa are also anticipated to contribute to market expansion, supported by improving healthcare infrastructure and growing awareness of advanced genomic technologies.
Access crucial information at unmatched prices!
Request your free sample report today & start making informed decisions powered by Credence Research!
Download Free Sample
Market Drivers:
Growing Demand for Precision Medicine:
The increasing emphasis on precision medicine is a significant driver of the NGS-based RNA Sequencing market. Precision medicine, which tailors medical treatment to the individual characteristics of each patient, relies heavily on comprehensive genomic data. RNA sequencing provides detailed insights into gene expression patterns, enabling the identification of specific biomarkers and therapeutic targets. For instance, data from the National Survey of Precision Medicine in Cancer Treatment conducted by the National Cancer Institute revealed that a nationally representative sample of 1,281 oncologists use genomic testing to inform treatment recommendations. As healthcare providers and researchers strive to deliver more personalized treatment options, the demand for RNA sequencing as a tool for understanding the molecular basis of diseases is growing. This trend is particularly strong in oncology, where RNA sequencing helps in identifying cancer-specific mutations and guiding targeted therapies. The broader adoption of precision medicine in clinical practice is expected to continue driving the growth of the RNA sequencing market.
Advances in Sequencing Technologies:
Technological advancements in next-generation sequencing (NGS) platforms have significantly contributed to the growth of the NGS-based RNA Sequencing market. These advancements have made RNA sequencing more efficient, accurate, and cost-effective, thereby broadening its applications in both research and clinical settings. Innovations such as increased sequencing depth, faster data processing, and enhanced bioinformatics tools have allowed for more detailed and comprehensive analysis of transcriptomes. These improvements not only reduce the time and cost associated with RNA sequencing but also enhance the ability to detect rare transcripts and low-abundance genes, expanding the scope of research and clinical diagnostics. As NGS technologies continue to evolve, their adoption in RNA sequencing is expected to increase, driving further market growth.
Rising Prevalence of Complex Diseases:
The rising prevalence of complex diseases such as cancer, neurological disorders, and autoimmune conditions is a key driver of the NGS-based RNA Sequencing market. These diseases often involve intricate genetic and molecular mechanisms that require in-depth analysis to understand fully. RNA sequencing enables researchers and clinicians to study gene expression patterns at an unprecedented level of detail, providing critical insights into disease pathogenesis. For instance, data from the National Health Interview Survey (NHIS) indicated that more than half (51.8%) of US adults had at least one of 10 selected diagnosed chronic conditions, and 27.2% had multiple chronic conditions. This capability is particularly valuable in cancer research, where understanding the molecular underpinnings of tumor development and progression is essential for developing effective therapies. As the burden of complex diseases continues to grow globally, the demand for RNA sequencing as a tool for disease research and diagnosis is expected to rise accordingly.
Integration of RNA Sequencing in Drug Discovery and Development:
The integration of RNA sequencing into drug discovery and development processes is another major driver of the NGS-based RNA Sequencing market. Pharmaceutical and biotechnology companies are increasingly using RNA sequencing to identify novel drug targets, understand drug mechanisms of action, and evaluate the efficacy and safety of therapeutic candidates. By providing a comprehensive view of gene expression changes in response to treatment, RNA sequencing helps to accelerate the drug development process and improve the success rate of new therapies. The growing focus on developing targeted and personalized therapies, particularly in oncology and rare diseases, is further fueling the adoption of RNA sequencing in the pharmaceutical industry. As drug discovery and development become more reliant on genomic data, the demand for RNA sequencing is expected to continue its upward trajectory.
Market Trends:
Increasing Application of Single-Cell RNA Sequencing:
A notable trend in the NGS-based RNA Sequencing market is the growing application of single-cell RNA sequencing (scRNA-seq). This technology allows researchers to analyze the gene expression of individual cells, providing a granular view of cellular functions and heterogeneity within tissues. As a result, scRNA-seq has become an invaluable tool in fields such as cancer research, immunology, and neuroscience, where understanding the behavior of individual cells can lead to new insights into disease mechanisms and therapeutic targets. The ability of scRNA-seq to uncover rare cell populations and track cellular responses to treatments is driving its adoption in both academic research and pharmaceutical development. As the technology becomes more accessible and cost-effective, its use is expected to expand further, contributing significantly to the growth of the RNA sequencing market.
Expanding Role in Clinical Diagnostics:
NGS-based RNA sequencing is increasingly being integrated into clinical diagnostics, a trend that is transforming the approach to diagnosing and managing complex diseases. In oncology, for example, RNA sequencing is used to identify specific gene fusions, mutations, and expression patterns that can guide targeted therapies. For instance, the FDA has finalized guidances to accelerate the development of reliable, beneficial next-generation sequencing-based tests1. Additionally, RNA sequencing has increased diagnostic rates by 8–36% across a variety of rare disorders and selected cohorts. This approach is also gaining traction in other areas, such as infectious disease diagnostics, where RNA sequencing can rapidly identify pathogens and characterize their resistance mechanisms. The shift towards using RNA sequencing in clinical settings is supported by advancements in sequencing accuracy, speed, and bioinformatics, which allow for the reliable interpretation of complex genomic data. As more clinical applications for RNA sequencing emerge, its role in personalized medicine is expected to grow, further driving market demand.
Advancements in Bioinformatics and Data Analysis:
The rapid advancements in bioinformatics and data analysis tools are significantly shaping the NGS-based RNA Sequencing market. As RNA sequencing generates vast amounts of data, the ability to efficiently process, analyze, and interpret this information is crucial. Recent developments in bioinformatics have led to more sophisticated algorithms and software platforms that can handle large datasets, identify meaningful patterns, and integrate various types of genomic data. These tools are essential for translating raw sequencing data into actionable insights, particularly in complex research areas such as transcriptomics and epigenetics. The continuous improvement of bioinformatics capabilities is making RNA sequencing more accessible to a broader range of researchers and clinicians, thereby expanding its applications and driving market growth.
Increasing Focus on RNA Sequencing for Biomarker Discovery:
Another significant trend in the NGS-based RNA Sequencing market is the increasing focus on using RNA sequencing for biomarker discovery. Biomarkers are critical for early disease detection, prognosis, and monitoring treatment responses, and RNA sequencing offers a powerful method for identifying these molecular indicators. For instance, RNA sequencing has been shown to increase the diagnostic rate by 10–35% for certain diseases. The technology’s ability to capture the dynamic nature of gene expression makes it particularly valuable for discovering biomarkers associated with complex diseases such as cancer and autoimmune disorders. As the demand for personalized medicine grows, so does the need for reliable biomarkers that can guide individualized treatment plans. RNA sequencing’s role in this area is expected to expand, with more research and clinical studies focusing on identifying and validating new biomarkers, thus driving further growth in the market.
Market Restraints and Challenges:
High Costs and Resource Limitations:
The NGS-based RNA Sequencing market faces significant challenges due to the high costs associated with sequencing technologies and the necessary infrastructure. While the cost of sequencing has decreased over the years, the overall expenses remain substantial, particularly for high-throughput platforms and the consumables required for large-scale studies. These costs can be prohibitive for smaller research institutions and clinical laboratories, especially in low- and middle-income regions, limiting the broader adoption of RNA sequencing. Additionally, the need for specialized equipment and trained personnel further exacerbates the financial burden, making it difficult for many organizations to fully integrate RNA sequencing into their research and clinical workflows.
Data Complexity and Interpretation Challenges:
Another major challenge in the NGS-based RNA Sequencing market is the complexity of the data generated. RNA sequencing produces vast amounts of data, including information on gene expression, alternative splicing, and non-coding RNAs. Managing, processing, and interpreting this data require advanced computational tools and bioinformatics expertise, which are not universally available. The complexity of RNA sequencing data makes it difficult to extract meaningful biological insights, particularly in clinical settings where timely and accurate decision-making is essential. The lack of standardized data analysis protocols and the need for specialized knowledge further complicate the use of RNA sequencing, potentially limiting its impact and slowing market growth.
Regulatory and Ethical Barriers:
Regulatory and ethical considerations also present significant challenges for the NGS-based RNA Sequencing market. As RNA sequencing is increasingly used in clinical diagnostics, it must meet stringent regulatory standards to ensure accuracy, reliability, and patient safety. Navigating the regulatory landscape can be time-consuming and costly, particularly when seeking approval for new applications. Furthermore, the use of RNA sequencing raises ethical concerns, especially regarding patient consent, data privacy, and the potential misuse of genetic information. These regulatory and ethical barriers can delay the adoption of RNA sequencing technologies in clinical practice and limit their overall market penetration.
Market Segmentation Analysis:
By Products and Services, the market is divided into sequencing platforms, consumables, services, and software. Sequencing platforms and consumables dominate the market due to the high demand for advanced equipment and reagents required for RNA sequencing. Services, including data analysis and sequencing services, are also growing rapidly as more organizations outsource complex sequencing tasks. Software solutions are increasingly critical for managing and analyzing the vast amounts of data generated by RNA sequencing.
By Technology, the market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, nanopore sequencing, and others. Sequencing by synthesis (SBS) remains the most widely used technology due to its high accuracy and scalability, making it the preferred choice for a wide range of research and clinical applications. Emerging technologies like nanopore sequencing are gaining traction for their ability to provide longer read lengths and real-time analysis.
By Application, the market includes applications in transcriptomics, epigenetics, small RNA sequencing, and others. Transcriptomics is the largest segment, driven by the growing need for comprehensive gene expression analysis in research and clinical diagnostics. Small RNA sequencing and epigenetics are also key areas of growth, particularly in cancer research and the study of complex diseases.
By End User, the market is segmented into academic and research institutions, pharmaceutical and biotechnology companies, and hospitals and clinical laboratories. Academic and research institutions hold the largest market share, driven by ongoing research initiatives and government funding. Pharmaceutical and biotechnology companies are increasingly adopting RNA sequencing for drug discovery and development, while hospitals and clinical laboratories are integrating RNA sequencing into personalized medicine and diagnostics.
Segmentation:
By Products and Services,
- Sequencing platforms,
- Consumables,
- Services,
- Others
By Technology,
- Synthesis (SBS),
- ion semiconductor sequencing,
- Nanopore sequencing,
By Application,
- Transcriptomics,
- Epigenetics,
- Small RNA sequencing,
- Others
By End User,
- Academic and research institutions,
- Pharmaceutical and biotechnology companies,
- Hospitals and clinical laboratories.
Based on Region
- North America
- Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Regional Analysis:
North America
North America holds the largest share of the NGS-based RNA Sequencing market, accounting for approximately 40% of the global market in 2023. This dominance is driven by the region’s strong presence of leading sequencing technology companies, significant research funding, and early adoption of advanced genomic technologies. The United States, in particular, is the primary contributor to this market share, supported by its robust healthcare infrastructure, extensive genomics research initiatives, and the presence of key players such as Illumina, Thermo Fisher Scientific, and Pacific Biosciences. Additionally, the growing emphasis on precision medicine and personalized therapies in the U.S. has further accelerated the adoption of RNA sequencing technologies. Canada also plays a crucial role, with increasing investments in healthcare research and a growing number of genomics research centers.
Europe
Europe is the second-largest region in the NGS-based RNA Sequencing market, holding approximately 30% of the global market share in 2023. The market in Europe is driven by strong government support for research and development, particularly in genomics and biotechnology. Countries such as the United Kingdom, Germany, and France are at the forefront of this growth, with substantial investments in genomic research and a well-established healthcare system that facilitates the adoption of advanced technologies. The UK’s initiatives, such as the 100,000 Genomes Project, have significantly contributed to the growth of RNA sequencing in clinical and research applications. Additionally, Europe is witnessing a rise in collaborations between academic institutions and industry players, further driving market expansion. The region’s focus on regulatory compliance and patient safety also supports the integration of RNA sequencing into clinical diagnostics.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for NGS-based RNA Sequencing, with a market share of approximately 20% in 2023. This rapid growth is attributed to the expanding healthcare infrastructure, increasing government investments in biotechnology, and rising prevalence of chronic diseases that require advanced diagnostic tools. China, Japan, and India are the key contributors to the market in this region. China, in particular, is investing heavily in genomics research and personalized medicine, supported by government initiatives and partnerships with global companies. Japan’s advanced technological capabilities and focus on innovation are also driving the adoption of RNA sequencing. Additionally, the growing middle class and increasing awareness of precision medicine in these countries are fueling demand for RNA sequencing technologies, making Asia-Pacific a key region for market growth.
Latin America and Middle East & Africa
Latin America and the Middle East & Africa collectively account for approximately 10% of the global NGS-based RNA Sequencing market in 2023. While these regions are currently smaller markets, they hold significant growth potential due to improving healthcare infrastructure and increasing awareness of advanced genomic technologies. In Latin America, countries like Brazil and Mexico are leading the market, driven by government initiatives to enhance healthcare and research capabilities. The Middle East & Africa region is also witnessing growth, supported by investments in healthcare modernization and the development of genomics research centers. However, challenges such as economic constraints and limited access to advanced technologies may slow market expansion in these regions. Despite these challenges, the improving healthcare landscape and growing focus on personalized medicine are expected to drive future growth in these emerging markets.
Key Player Analysis:
- Agilent Technologies, Inc. (US)
- BGI (China)
- Eurofins Scientific (Luxembourg)
- Hoffmann-La Roche Ltd (Switzerland)
- GENEWIZ, Inc. (US)
- Hamilton Company (US)
- Illumina Inc. (US)
- Macrogen Inc. (South Korea)
- Oxford Nanopore Technologies plc (UK)
- PerkinElmer Inc. (US)
- QIAGEN (Germany)
- Takara Bio Inc. (Japan)
- Tecan Trading AG (Switzerland)
- Thermo Fischer Scientific Inc. (US)
- Zymo Research Corporation (US)
Competitive Analysis:
The NGS-based RNA Sequencing market is highly competitive, with several key players dominating the industry through continuous innovation and extensive product portfolios. Leading companies such as Illumina, Thermo Fisher Scientific, and Pacific Biosciences hold significant market shares due to their advanced sequencing platforms, strong global distribution networks, and ongoing investments in research and development. These companies are at the forefront of technological advancements, offering comprehensive solutions that include sequencing instruments, consumables, and bioinformatics tools. The competitive landscape is also shaped by emerging players and niche companies that are developing specialized sequencing technologies and targeting specific applications. Strategic partnerships, mergers, and acquisitions are common in this market as companies seek to expand their capabilities and market reach. As the demand for RNA sequencing grows, driven by applications in precision medicine, drug discovery, and diagnostics, competition is expected to intensify, fostering further innovation and market expansion.
Recent Developments:
- In October 2022, PacBio launched the multiplexed array sequencing (MAS-Seq) kit in partnership with the Broad Institute of MIT and Harvard and 10x Genomics. This kit enables long-read single-cell RNA sequencing to detect and characterize novel isoforms, driver mutations, and cancer fusion genes.
- In March 2022, Quantbio introduced the sparQ RNA-Seq HMR kit, an ultra-fast RNA next-generation sequencing (NGS) library preparation tool. The kit integrates ribosomal RNA (rRNA) and globin mRNA depletion, allowing researchers to generate high-quality stranded transcriptome libraries from challenging FFPE or low-input human, mouse, and rat samples within five hours.
- In March 2022, Element Biosciences Inc. released the Element AVITI System, a benchtop sequencer that offers a unique combination of performance, affordability, and flexibility, along with related consumables for next-generation sequencing.
Market Concentration & Characteristics:
The NGS-based RNA Sequencing market is moderately concentrated, with key players like Illumina, Thermo Fisher Scientific, and Pacific Biosciences holding substantial market shares due to their advanced technologies and comprehensive product lines. These companies dominate the market through continuous innovation, strong global distribution networks, and significant investments in research and development. The market is characterized by rapid technological progress, particularly in sequencing accuracy, throughput, and bioinformatics integration, which enhances data analysis capabilities. While these leading firms maintain a strong presence, the market also includes emerging players focused on specialized applications and innovative approaches. This creates a dynamic competitive landscape where both established and new entrants contribute to market growth. Collaboration between industry leaders, research institutions, and healthcare provider’s further drives advancements, ensuring the market remains at the forefront of genomic research and clinical diagnostics.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Report Coverage:
The research report offers an in-depth analysis based on By Products and services, By Technology, By Application and By End User. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook:
- Increased adoption in personalized medicine will drive demand for RNA sequencing technologies.
- Advancements in single-cell RNA sequencing will expand research applications and precision diagnostics.
- Integration of AI and machine learning will enhance data analysis and interpretation in RNA sequencing.
- Growing prevalence of chronic diseases will boost the use of RNA sequencing in clinical settings.
- Continued reduction in sequencing costs will make RNA sequencing more accessible across diverse markets.
- Expansion of bioinformatics tools will improve the efficiency and accuracy of RNA sequencing data processing.
- Rising investments in genomics research will propel the development of new RNA sequencing applications.
- Emerging markets in Asia-Pacific and Latin America will see significant growth in RNA sequencing adoption.
- Increased collaboration between industry and academia will accelerate technological advancements in RNA sequencing.
- Expansion of regulatory approvals will facilitate the integration of RNA sequencing in clinical diagnostics globally.
